RxDoctor Payments Data

Trenton Timmer, PA

Neurology · Hickory, NCNPI 1003444654

Payments from drug & device makers

$7,920in general payments, 2019–2025

Across 457 payments — averaging $17.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Teva Pharmaceuticals USA, Inc.$918
  • Pfizer$595
  • MDD US Operations, LLC$517
  • EMD Serono, Inc.$483
  • Novartis$438
  • plus $4K from 47 others

What the payments were for

  • Consulting fees$3004%
  • Speaking & faculty fees$220%
  • Food & beverage$7,41794%
  • Education$1812%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,920 in reported general payments places this provider in the 65th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$41,647
Medicare patients
205
Services billed
1,379

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant121$190,394
XywavSodium,calcium,mag,pot Oxybate14$185,423
Aimovig AutoinjectorErenumab-Aooe142$138,719
Nurtec OdtRimegepant Sulfate110$113,829
AustedoDeutetrabenazine14$104,940
Avonex (4 Pack)Interferon Beta-1a12$96,437
VumerityDiroximel Fumarate11$95,954
QuliptaAtogepant73$85,975
Emgality PenGalcanezumab-Gnlm54$39,154
Zembrace SymtouchSumatriptan Succinate24$37,872
TopamaxTopiramate25$25,402
Sumatriptan Succinate87$13,247
Pregabalin294$10,089
Ajovy SyringeFremanezumab-Vfrm12$8,566
Gabapentin254$7,188

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$1,254$276,368194 claims
BiogenAvonex (4 Pack), Vumerity$184$192,39123 claims
PfizerNurtec Odt$595$113,829110 claims
Teva Pharmaceuticals USA, Inc.Austedo$918$104,94014 claims
Upsher-smith Laboratories LLCZembrace Symtouch, Topiramate$17$39,334250 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 566 neurology providers in North Carolina.

Other neurology in Hickory

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →